Trials
Search / Trial NCT06438900

Investigating the Link Between Advanced Glycation End Products (AGEs) and Muscle Wasting in Sarcobesity

Launched by AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARITA · May 27, 2024

Trial Information

Current as of February 19, 2025

Recruiting

Keywords

Advanced Glycation End Products Sarcobesity Obesity Sarcopenic

ClinConnect Summary

This clinical trial is studying the relationship between certain substances in our diet called Advanced Glycation End Products (AGEs) and muscle loss in people who are both obese and have type 2 diabetes. Researchers want to see if higher levels of AGEs in the body are linked to greater muscle loss in these patients, which can lead to more serious health issues, including diabetes complications. The study will involve measuring AGE levels in the skin and looking at how these levels relate to the severity of muscle loss in participants.

To be eligible for this trial, participants need to be adults aged 65 to 74, both men and women, who are classified as obese and have well-controlled type 2 diabetes. They should not have certain other health conditions, like inflammatory bowel disease or cancer. If you join the study, you can expect to provide some health information and undergo tests to measure AGEs and assess muscle health. This research aims to better understand how dietary factors contribute to muscle loss and related health problems, which could help in developing ways to improve the health of people facing these challenges.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients of both sexes.
  • Adults.
  • BMI compatible with obesity and a diagnosis of type 2 diabetes under good metabolic control (HbA1c \< 7.5%) within 15 years of entry into the study or diagnosis of lipodystrophy (included in the European Consortium of Lipodystrophies (ECLip) Registry (eclip-web.org))
  • Exclusion Criteria:
  • Age under 18 years.
  • Secondary obesity or genetic diseases (Prader-Willi Syndrome, Down Syndrome); metabolic and endocrine disorders (Cushing's syndrome, hypothyroidism).
  • Subjects with: Inflammatory Bowel Disease (IBD), cancer.
  • Confirmed or planned pregnancy during the study participation months.

Trial Officials

Flavia Prodam, MD PhD

Principal Investigator

AOU Maggiore della Carità di Novara

About Azienda Ospedaliero Universitaria Maggiore Della Carita

Azienda Ospedaliero Universitaria Maggiore della Carità is a leading academic hospital in Italy, renowned for its commitment to advancing healthcare through innovative clinical research and comprehensive patient care. With a focus on a wide range of medical specialties, the institution collaborates with various research entities to conduct rigorous clinical trials aimed at improving treatment outcomes and enhancing medical knowledge. Its state-of-the-art facilities and multidisciplinary approach ensure high-quality standards in research, fostering an environment conducive to scientific discovery and the development of new therapeutic strategies.

Locations

Novara, , Italy

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0